

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和鉑醫藥控股有限公司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON A COLLABORATION AGREEMENT WITH
THE MOUNT SINAI HEALTH SYSTEM AND IN CONNECTION WITH
NEUTRALIZING COVID-19 ANTIBODY

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company is pleased to announce that the Company was informed by The Icahn School of Medicine at Mount Sinai (“**Mount Sinai**”), a part of Mount Sinai Health System, that it has entered into an exclusive license (the “**License**”) agreement with a third party over a collection of antibodies having SARS-COV-2 (COVID-19) neutralizing properties. The License also contemplated that the contracting parties may pursue future collaborations in developing humanized monoclonal antibodies for therapeutic applications.

Mount Sinai has developed a collection of the COVID-19 virus neutralizing antibodies through a collaboration with Harbour BioMed US, Inc., a subsidiary of the Company pursuant to an academic collaboration agreement entered into between Mount Sinai and the Company dated 11 October 2019 (the “**Collaboration Agreement**”). Pursuant to the Collaboration Agreement, the Company is entitled to receive 25% of the proceeds Mount Sinai derives from the License, which is a research program contemplated in the Collaboration Agreement.

This announcement is made by the Company on a voluntary basis. The Collaboration Agreement is of a revenue nature in the ordinary and usual course of business of the Group and does not constitute notifiable transaction under Chapter 14 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

ABOUT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care. It is the medical school for the Mount Sinai Health System, which includes eight hospital campuses, and has more than 5,000 faculty and nearly 2,000 students, residents and fellows. Their unwavering pursuit of intellectual exchange, breakthrough research, and multidisciplinary teamwork propels them ever forward in biomedical discoveries and advances. They pursue ideas that often challenge conventional wisdom to revolutionize the practice of medicine and produce dramatically better outcomes for patients. They make big, bold bets by investing in radical free thinkers and technology at the cutting edge.

ABOUT THE MOUNT SINAI HEALTH SYSTEM

The Mount Sinai Health System is an integrated health care system providing exceptional medical care to our local and global communities.

Encompassing the Icahn School of Medicine at Mount Sinai and eight hospital campuses in the New York metropolitan area, as well as a large, regional ambulatory footprint, Mount Sinai is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties. The Mount Sinai Health System was created from the combination of the Mount Sinai Medical Center and Continuum Health Partners, which both agreed unanimously to combine the two entities in July 2013.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market any of our products referenced in this announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 19 July 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.